SequelSEC

Strata Critical Medical, Inc. SRTA

Services-Health Services · CIK 0001779128 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$197.14M
Fiscal year ended 2025-12-31
Operating income
-$22.35M
Fiscal year ended 2025-12-31
Free cash flow
-$58.51M
Fiscal year ended 2025-12-31

Strata Critical Medical, Inc. (SRTA) reported revenue of $197.14M and net income of $41.35M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Strata Critical Medical, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Health Services.

Income

Strata Critical Medical, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-09-302020-09-302019-09-30
Revenue$197.14M$146.82M$225.18M$146.12M$50.53M$23.43M$31.20M
Cost of revenue$156.02M$117.23M$183.06M$123.84M$40.01M$21.11M$26.50M
Gross profit$41.13M$29.59M$42.12M$22.28M$10.52M$2.33M$4.70M
Operating income-$22.35M-$22.52M-$68.12M-$53.53M-$24.09M-$10.36M-$11.54M
Net income$41.35M-$27.31M-$56.08M-$27.26M-$40.05M-$10.16M-$10.84M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 82.09Mshares 77.50Mshares 73.52Mshares 71.24Mshares 42.88Mshares 25.21Mshares 25.14M
Pretax income-$20.07M-$16.16M-$57.54M-$28.03M-$43.70M-$10.16M-$10.84M
Income tax expense$0$0-$1.47M-$772.00K-$3.64M$0$0
Diluted EPS$0.50$-0.35$-0.76$-0.38$-0.93$-0.40$-0.43
Selling, general & administrative$60.88M$50.86M$105.61M$70.26M$32.93M$11.82M$15.49M
General & administrativeUnavailable$81.71M$95.17M$62.51M$30.14M$9.29M$10.48M
Selling & marketingUnavailable$7.95M$10.44M$7.75M$2.78M$2.53M$5.01M

Balance

Strata Critical Medical, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-09-302020-09-302019-09-30
Cash & equivalents$30.97M$18.38M$27.87M$41.34M$6.95M$12.16M$22.18M
Total assets$325.47M$256.68M$294.94M$325.02M$343.39M$17.72M$276.99M
Current assets$126.19M$160.74M$206.26M$218.13M$314.45M$14.38MUnavailable
Total liabilities$46.40M$34.74M$60.64M$50.54M$52.16M$6.64M$9.98M
Current liabilities$19.79M$22.73M$35.49M$26.61M$9.53M$6.34M$353.21K
Total equity incl. NCI$279.07M$221.94M$234.30M$274.49M$291.23M$11.08M$20.74M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$244.64M$244.04M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$39.96M$19.82M$21.00M$10.88M$3.76M$1.09MUnavailable
Goodwill$88.21M$15.54M$13.33M$39.44M$13.27M$0Unavailable
Long-term debtUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Strata Critical Medical, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-09-302020-09-302019-09-30
Operating cash flow-$48.91M-$2.52M-$32.35M-$37.13M-$15.62M-$10.82M-$10.30M
Capital expenditures$9.60M$30.86M$2.11M$730.00K$297.00K$377.00K$604.00K
Investing cash flow$69.75M-$1.02M$17.09M$79.34M-$321.34M-$377.00K-$1.05M
Financing cash flow-$8.91M-$5.76M-$76.00K-$1.08M$332.26M$1.18M$116.00K
Net change in cash$11.58M-$9.37M-$15.40M$41.20M-$4.69M-$10.02M-$11.24M
Stock-based compensation$17.83M$19.89M$12.50M$8.28M$9.62M$490.00K$317.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$244.00K$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$8.18M$5.96M$7.11M$5.72M$596.00K$526.00K$472.00K

Derived

Strata Critical Medical, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-09-302020-09-302019-09-30
Free cash flow-$58.51M-$33.38M-$34.46M-$37.86M-$15.91M-$11.20M-$10.91M
Gross margin20.9%20.2%18.7%15.2%20.8%9.9%15.1%
Operating margin-11.3%-15.3%-30.3%-36.6%-47.7%-44.2%-37.0%
FCF margin-29.7%-22.7%-15.3%-25.9%-31.5%-47.8%-35.0%
SBC / revenue9.0%13.5%5.6%5.7%19.0%2.1%1.0%
Current ratio6.38x7.07x5.81x8.20x32.99x2.27xUnavailable
Revenue YoY growth34.3%-34.8%54.1%Unavailable115.6%-24.9%Unavailable
Net margin21.0%-18.6%-24.9%-18.7%-79.3%-43.4%-34.7%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue4.9%21.0%0.9%0.5%0.6%1.6%1.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SRTA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ATPC DCGO INNV LDDD LFST NPLY OMDA PIII PNTG PRVA USPH VSEE

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-09-30

Difference 244636825 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2019-09-30

Difference 2231671 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.